Trials / Completed
CompletedNCT05613296
Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP
Real World Evaluation Among Italian Centers of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With Immune Thrombocytopenia (ITP)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 95 (actual)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective and prospective multicenter observational study with the aim to evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to other treatments.
Detailed description
This is a retrospective and prospective multicenter observational study with the aim to evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to other treatments. All patients who received at least one dose of Fostamatinib between October 1st, 2021 and April 1st, 2023 outside interventional clinical trials in Italy in the participating centers will be invited to participate in the study. Every patient will be observed for at least 6 months until October 1st, 2023.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fostamatinib | Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months. |
Timeline
- Start date
- 2023-05-05
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
- First posted
- 2022-11-14
- Last updated
- 2025-04-30
Locations
21 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT05613296. Inclusion in this directory is not an endorsement.